$-0.38 EPS Expected for Arbutus Biopharma (ABUS); Choate Investment Advisors Has Lifted Its Coca Cola Co (KO) Position

February 13, 2018 - By Ellis Scott

Choate Investment Advisors increased Coca Cola Co (KO) stake by 0.92% reported in 2017Q3 SEC filing. Choate Investment Advisors acquired 525 shares as Coca Cola Co (KO)’s stock rose 6.48%. The Choate Investment Advisors holds 57,501 shares with $2.59B value, up from 56,976 last quarter. Coca Cola Co now has $187.56B valuation. The stock increased 0.11% or $0.05 during the last trading session, reaching $44.02. About 6.22 million shares traded. The Coca-Cola Company (NYSE:KO) has declined 0.95% since February 13, 2017 and is downtrending. It has underperformed by 17.65% the S&P500.

Analysts expect Arbutus Biopharma Corporation (NASDAQ:ABUS) to report $-0.38 EPS on March, 20.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.38 EPS. After having $-0.17 EPS previously, Arbutus Biopharma Corporation’s analysts see 123.53% EPS growth. The stock decreased 0.47% or $0.025 during the last trading session, reaching $5.275. About 41,412 shares traded. Arbutus Biopharma Corporation (NASDAQ:ABUS) has declined 2.31% since February 13, 2017 and is downtrending. It has underperformed by 19.01% the S&P500.

Among 22 analysts covering Coca-Cola (NYSE:KO), 12 have Buy rating, 1 Sell and 9 Hold. Therefore 55% are positive. Coca-Cola had 69 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of The Coca-Cola Company (NYSE:KO) has “Hold” rating given on Monday, October 23 by Stifel Nicolaus. The firm has “Buy” rating given on Friday, November 10 by RBC Capital Markets. The firm has “Neutral” rating given on Tuesday, March 15 by Susquehanna. The rating was upgraded by Evercore to “Outperform” on Friday, January 12. Barclays Capital reinitiated the stock with “Equal Weight” rating in Friday, August 7 report. Morgan Stanley downgraded The Coca-Cola Company (NYSE:KO) on Friday, December 16 to “Equal-Weight” rating. The firm has “Outperform” rating given on Wednesday, April 19 by Credit Suisse. Sterne Agee CRT initiated The Coca-Cola Company (NYSE:KO) on Tuesday, July 21 with “Buy” rating. On Monday, July 31 the stock rating was maintained by BMO Capital Markets with “Market Perform”. On Friday, October 27 the stock rating was maintained by Cowen & Co with “Hold”.

Investors sentiment decreased to 0.8 in Q3 2017. Its down 0.14, from 0.94 in 2017Q2. It dived, as 48 investors sold KO shares while 641 reduced holdings. 94 funds opened positions while 456 raised stakes. 2.73 billion shares or 0.93% more from 2.70 billion shares in 2017Q2 were reported. Segall Bryant And Hamill Lc holds 0.07% or 70,796 shares. Lakeview Cap Limited Liability reported 1.48% stake. First Trust Lp invested 0.26% of its portfolio in The Coca-Cola Company (NYSE:KO). Profund Limited Liability holds 99,479 shares or 0.19% of its portfolio. Jag Capital Limited Com stated it has 33,787 shares. Hudock Cap Limited Com invested in 34,766 shares or 0.73% of the stock. Lee Danner & Bass owns 0.31% invested in The Coca-Cola Company (NYSE:KO) for 64,892 shares. Atlantic Gru Lc has invested 0.14% in The Coca-Cola Company (NYSE:KO). Asset Mgmt Of Georgia Inc Ga Adv has invested 1.87% in The Coca-Cola Company (NYSE:KO). Barnett holds 0.01% of its portfolio in The Coca-Cola Company (NYSE:KO) for 648 shares. Howland Capital Mgmt Llc holds 0.22% or 59,355 shares in its portfolio. The Missouri-based Duncker Streett Inc has invested 0.22% in The Coca-Cola Company (NYSE:KO). 86,649 are owned by Greenwood Capital Associate Ltd Liability. Df Dent & accumulated 0.04% or 36,263 shares. Duff & Phelps Mngmt accumulated 0.03% or 43,170 shares.

Since August 15, 2017, it had 0 insider purchases, and 3 sales for $5.80 million activity. RIVERA ALFREDO had sold 28,232 shares worth $1.30M. 84,400 The Coca-Cola Company (NYSE:KO) shares with value of $4.01 million were sold by HAYS ED. Shares for $719,250 were sold by LONG ROBERT EDWARD. SMITH BRIAN JOHN had sold 100,000 shares worth $4.61M on Tuesday, August 15. $1.07 million worth of The Coca-Cola Company (NYSE:KO) was sold by Waller Kathy N on Tuesday, January 16.

Choate Investment Advisors decreased Vanguard Dividend Apprec Etf (VIG) stake by 3,340 shares to 43,390 valued at $4.11B in 2017Q3. It also reduced Jp Morgan Chase & Co (NYSE:JPM) stake by 1,115 shares and now owns 110,493 shares. Ishares Msci Eafe Etf (EFA) was reduced too.

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 30 by Chardan Capital Markets. The firm has “Market Perform” rating given on Tuesday, November 7 by Leerink Swann. JMP Securities initiated the stock with “Mkt Outperform” rating in Wednesday, September 2 report. Leerink Swann downgraded the stock to “Market Perform” rating in Friday, August 5 report. The rating was upgraded by Chardan Capital Markets on Tuesday, April 4 to “Buy”. The firm has “Neutral” rating given on Thursday, June 16 by Chardan Capital Markets. Chardan Capital Markets downgraded the stock to “Sell” rating in Friday, July 8 report. The company was downgraded on Tuesday, December 13 by Chardan Capital Markets. The company was upgraded on Friday, October 14 by Chardan Capital Markets. The stock has “Buy” rating by Chardan Capital Markets on Friday, August 4.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $290.40 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The company's lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: